Categories: News

CYIOS Corporation (OTC: CYIO) Announces Leadership Transition and Engages Artificial Intelligence (AI) and Software-as-a-Service (SaaS) advisors

MELBOURNE, Australia and PALM BEACH, Fla., Oct. 21, 2025 (GLOBE NEWSWIRE) — CYIOS Corporation (OTC: CYIO) today announced that David Lewis has stepped down from his roles with CYIOS, and as part of this transition, he has voluntarily agreed to return 16,560 Series D Preferred Shares to the Company, and cancel all outstanding salary and loan obligations. This decisive step strengthens the company’s balance sheet, simplifies its capital structure, and positions CYIOS for its next stage of growth. We wish David all the best for his next endeavor.

CYIOS is also working closely with its independent auditor to complete two years of PCAOB-audited financial statements, with 2024 being fully completed, which is an important milestone toward enhancing transparency and compliance. In parallel, the company continues to focus on increasing working capital through strategic investment initiatives aimed at paying down Noir Medical Supplies’ debt obligations, a key priority expected to be completed by mid-2026.

“These are meaningful milestones in strengthening CYIOS’ foundation for growth,” said Mr. John O’Shea, Chairman and CEO of CYIOS Corporation. “We remain committed to disciplined financial management, profitable expansion, and delivering long-term value to our shareholders.”

Mr. O’Shea is also excited to announce that CYIOS is now looking to engage Artificial Intelligence (AI) and Software-as-a-Service (SaaS) advisors to help map out CyioIQ: CYIO’s AI-Driven Medical Platform scope, architecture, design, business case, and build cost for a comprehensive AI-driven platform. This initiative aims to maximize CYIOS’s position within the medical and health supply industry. The implementation of AI is expected to streamline operations within Noir Medical Supplies, driving greater efficiency, strengthening bottom-line profitability, and unlocking potential new revenue streams through third-party distribution partnerships with other industry players. More information on this exciting development will follow.

CYIOS Corporation
CYIOS Corporation (OTC: CYIO) is a diversified holding company focused on building, acquiring, and operating innovative businesses across multiple industries, including medical supplies, technology, and fintech. Through its subsidiary Noir Medical Supplies, CYIOS continues to expand its presence in the U.S. medical distribution sector, emphasizing operational excellence and sustainable profitability.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on current expectations and assumptions that involve risks and uncertainties that could cause actual results to differ materially. CYIOS undertakes no obligation to update or revise any forward-looking statements except as required by law.

Contact:
Investor Relations
CYIOS Corporation
info@cyioscorporation.com
www.cyioscorporation.com

Staff

Recent Posts

RPI Consultants Presents Annual Scholarship to Healthcare Technology Professional

BALTIMORE, Feb. 5, 2026 /PRNewswire/ -- RPI Consultants, a leading ERP implementation, optimization, and software firm…

2 hours ago

BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration

LONDON, Feb. 5, 2026 /PRNewswire/ -- BioPhorum, the pharmaceutical industry's most trusted collaborative network for…

2 hours ago

BC Platforms partners with OmicsBank to expand access to large-scale real-world and multi-omics data from India and the UAE

Patient catchment now includes 187 million+ patient lives, enables advanced analytics and AI modeling for…

2 hours ago

Electron Microscopy Market to Reach $10.3 billion, Globally, by 2034 at 8.1% CAGR: Allied Market Research

The electron microscopy market is driven by rapid advancements in nanotechnology, increase in demand for…

2 hours ago

BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery

VANCOUVER, BC / ACCESS Newswire / February 5, 2026 / BioNxt Solutions Inc. ("BioNxt" or…

2 hours ago

Pentixapharm Announces Peer-Reviewed Phase 2 Data Back Use of PENTIXAFOR as a Superior Non-invasive PET-Diagnostic for Primary Aldosteronism

In the study, [68Ga]Ga-Pentixafor PET/CT was well tolerated and demonstrated high specificity and moderate sensitivity…

5 hours ago